Nan Wu
- Cancer Research top 1%
- Molecular Biology top 2%
- Congenital heart defects research 10
- Rheumatology top 2%
- Osteomyelitis and Bone Disorders Research 12
- Cell Biology top 5%
-
- Connective tissue disorders research 29
- Genomics and Rare Diseases 9
-
- Scoliosis diagnosis and treatment 18
- Spinal Fractures and Fixation Techniques 14
-
- Genetic factors in colorectal cancer 12
- Spine and Intervertebral Disc Pathology 10
Nan Wu
216 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 173
- Cancer Research 1.5k
- Molecular Biology 2.7k
- Rheumatology 373
- Cell Biology 359
- Orthopedics and Sports Medicine 166
Countries citing papers authored by Nan Wu
This map shows the geographic impact of Nan Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Wu more than expected).
Fields of papers citing papers by Nan Wu
This network shows the impact of papers produced by Nan Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Wu. The network helps show where Nan Wu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nan Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 12 | |
| 7 | 2024 | 2 | |
| 8 | 2024 | 0 | |
| 9 | 2024 | 8 | |
| 10 | 2024 | 0 | |
| 11 | 2024 | 4 | |
| 12 | 2023 | 2 | |
| 13 | 2023 | 8 | |
| 14 | 2023 | 10 | |
| 15 | 2022 | 8 | |
| 16 | 2022 | 4 | |
| 17 | 2021 | 32 | |
| 18 | Piezo1/2 mediate mechanotransduction essential for bone formation through concerted activation of NFAT-YAP1-ß-cateninbreakdown → | 2020 | 266 |
| 19 | 2020 | 82 | |
| 20 | Serum IgG4 elevation in SAPHO syndrome: does it unmask a disease activity marker? | 2019 | 13 |
About Nan Wu
Nan Wu is a scholar working on Rheumatology, Genetics, Pathology and Forensic Medicine, Cancer Research and Surgery, having authored 245 papers that have together received 4.8k indexed citations. Recurring topics across this work include Connective tissue disorders research (29 papers), Scoliosis diagnosis and treatment (18 papers), Spinal Fractures and Fixation Techniques (14 papers), Osteomyelitis and Bone Disorders Research (12 papers), Genetic factors in colorectal cancer (12 papers), Spine and Intervertebral Disc Pathology (10 papers), Congenital heart defects research (10 papers) and Genomics and Rare Diseases (9 papers). The work is most often cited by research in Cancer Research (1.5k citations), Molecular Biology (2.7k citations), Rheumatology (373 citations), Cell Biology (359 citations) and Orthopedics and Sports Medicine (166 citations). Nan Wu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Xiaolong Qi, Junhua Xiao, Wang Ma, Dahong Zhang, Xiang Wang, Andrew P. McMahon, Shinji Takada, Yoshiaki Yoshikawa, Terry P. Yamaguchi and Zhihong Wu. Their work appears in journals such as Orphanet Journal of Rare Diseases, Journal of Medical Genetics, Genes, Clinical Rheumatology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.